The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-1801
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer ; volume:5 ; number:1 ; day:3 ; month:8 ; year:2016 ; pages:1-7 ; date:12.2016
SpringerPlus ; 5, Heft 1 (3.8.2016), 1-7, 12.2016
- Urheber
-
Yufen, Xu
- Beteiligte Personen und Organisationen
-
Binbin, Song
Wenyu, Chen
Jialiang, Liu
Xinmei, Yang
SpringerLink (Online service)
- DOI
-
10.1186/s40064-016-2873-2
- URN
-
urn:nbn:de:1111-201608049598
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yufen, Xu
- Binbin, Song
- Wenyu, Chen
- Jialiang, Liu
- Xinmei, Yang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
Leptomeningeal metastases from solid tumours
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Leptomeningeal Metastases: New Opportunities in the Modern Era
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
Leptomeningeal metastases from solid tumours
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Leptomeningeal Metastases: New Opportunities in the Modern Era
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
Leptomeningeal metastases from solid tumours
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation